Perceptive Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,485,420
| Closed | -$84.9M | – | 98 |
|
|
2025
Q4 | $84.9M | Hold |
6,485,420
| – | – | 1.51% | 22 |
|
|
2025
Q3 | $47.2M | Hold |
6,485,420
| – | – | 1.36% | 26 |
|
|
2025
Q2 | $34.8M | Hold |
6,485,420
| – | – | 1.29% | 21 |
|
|
2025
Q1 | $34.6M | Hold |
6,485,420
| – | – | 1.22% | 25 |
|
|
2024
Q4 | $58M | Hold |
6,485,420
| – | – | 1.6% | 18 |
|
|
2024
Q3 | $71.4M | Hold |
6,485,420
| – | – | 1.51% | 18 |
|
|
2024
Q2 | $59M | Hold |
6,485,420
| – | – | 1.42% | 20 |
|
|
2024
Q1 | $91.2M | Buy |
6,485,420
+2,481,350
| +62% | +$30.9M | 1.6% | 20 |
|
|
2023
Q4 | $30.8M | Buy |
4,004,070
+1,814,608
| +83% | +$10M | 0.69% | 41 |
|
|
2023
Q3 | $16.3M | Hold |
2,189,462
| – | – | 0.54% | 51 |
|
|
2023
Q2 | $18.2M | Hold |
2,189,462
| – | – | 0.53% | 53 |
|
|
2023
Q1 | $29.1M | Hold |
2,189,462
| – | – | 0.86% | 38 |
|
|
2022
Q4 | $32.6M | Buy |
2,189,462
+908,265
| +71% | +$9.37M | 0.92% | 34 |
|
|
2022
Q3 | $11.6M | Hold |
1,281,197
| – | – | 0.34% | 61 |
|
|
2022
Q2 | $3.84M | Hold |
1,281,197
| – | – | 0.12% | 83 |
|
|
2022
Q1 | $8.6M | Hold |
1,281,197
| – | – | 0.17% | 87 |
|
|
2021
Q4 | $6.91M | Sell |
1,281,197
-678,455
| -35% | -$4.46M | 0.11% | 106 |
|
|
2021
Q3 | $17.3M | Buy |
1,959,652
+678,454
| +53% | +$6.5M | 0.25% | 75 |
|
|
2021
Q2 | $16.2M | Buy |
1,281,198
+958,939
| +298% | +$12.5M | 0.21% | 90 |
|
|
2021
Q1 | $5.59M | Buy |
+322,259
| New | +$5.82M | 0.07% | 111 |
|
Perceptive Advisors's ATXS Position: Q1 2026 in Review
Perceptive Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 6,485,420 shares — an estimated $84.9M sold.
Perceptive Advisors first reported a position in ATXS in Q1 2021 and held it in 20 quarters. The position peaked at $91.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Perceptive Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Perceptive Advisors sold 6,485,420 Astria Therapeutics shares in Q1 2026, an estimated $84.9M.
- Perceptive Advisors first reported a position in Astria Therapeutics in Q1 2021 and held it in 20 quarters.
- Perceptive Advisors's Astria Therapeutics position peaked at $91.2M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.